Real-World Analysis of Treatment Delays in Metastatic Non-Small Cell Lung Cancer: Demographic, Clinical, and Payer Drivers
The Economic Burden of Metastatic Non-Small Cell Lung Cancer in US Patients without an EGFR or ALK Mutation
